Project description
Novel drugs stop influenza replication
Influenza viruses are responsible for the seasonal flu, affecting millions of people worldwide every year. Given the potential of influenza to cause pandemics with devastating effects on human lives and the economy, there is a pressing need for effective antiviral drugs with a reduced risk of causing viral escape. Scientists of the EU-funded FluAttack project have identified a new family of molecules as potent inhibitors of influenza viruses. These molecules target a cellular function paramount to virus survival and will undergo further testing and characterisation in models of influenza infection. The project aims to support the future development and pre-clinical validation of these anti-flu drugs.
Objective
With 3 to 5 million severe cases and up to 650,000 deaths per year worldwide, influenza viruses are not only major human pathogens, they are also a heavy economic burden to our societies. In addition, influenza pandemics can occur at any time with potential devastating effects in terms of lives and costs. Solutions to prevent infection, to treat severe influenza cases and to respond to a severe pandemic are currently extremely limited and rely on vaccination and on only few approved molecules. All these solutions have their limitations with respect to efficacy and all face the problem of viral resistance. Thus, the demand for new options against influenza infections is high. The World Health Organization (WHO) and influenza virus specialists agree that innovative and effective anti-influenza compounds with a reduced risk of viral escape are urgently needed. The main goal of this ERC PoC is to provide key data on a promising innovative therapeutic solution identified in the lab. Taking advantage of a powerful screening system we have developed during the ERC StG ANTIViR, we have identified a family of molecules as potent inhibitors of influenza virus (with IC50<100nM). The mode of action of these molecules is known and they actually target a cellular function essential to all influenza viruses. Preventing viral replication by targeting a cellular function is a novel approach, predicted to strongly reduce the risk of drug resistance. Importantly, one of our hits went through several phase II and III clinical trials as an anti-cancer agent, making this molecule a perfect candidate for drug repurposing. In this context, the specific objectives of this ERC PoC are: i) to further characterise and validate our best hit, in particular in commercial 3D human airway epithelial cells and in vivo in a mouse model, and ii) to secure IPR and to establish an exploitation strategy plan (patent licensing or creation of a start-up) to support future development and preclinical tests.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine pharmacology and pharmacy drug discovery
- medical and health sciences health sciences public health epidemiology pandemics
- medical and health sciences health sciences infectious diseases RNA viruses influenza
- medical and health sciences basic medicine pharmacology and pharmacy drug resistance
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs antivirals
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC)
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
ERC-POC - Proof of Concept Grant
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) ERC-2019-PoC
See all projects funded under this callHost institution
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
75654 PARIS
France
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.